· Event impact
Bristol Myers Squibb seen as undervalued despite patent cliffs.
Transmission path
A major pharmaceutical company trading at a low valuation with a high dividend yield, despite facing patent cliffs, could attract value investors seeking income and potential upside if the company successfully navigates its pipeline and manages patent expirations.
Market mechanism
A major pharmaceutical company trading at a low valuation with a high dividend yield, despite facing patent cliffs, could attract value investors seeking income and potential upside if the company successfully navigates its pipeline and manages patent expirations.
Extended read
Bristol Myers Squibb (BMY) is currently trading at what is considered an unusually low valuation, with a forward earnings multiple of approximately 10 times and a trailing free cash flow multiple of 9.9 times. This valuation stands out given the company's substantial revenue projections. BMY anticipates generating between $46 billion and $47.5 billion in annual revenue and offers an attractive dividend yield exceeding 4%. These financial metrics typically suggest a higher valuation, but the market appears to be discounting the stock. The primary concern weighing on BMY's valuation is the impending patent cliffs for key blockbuster drugs such as Eliquis and Opdivo. Successful pipeline development and strategic management of these patent expirations will be crucial for the company to unlock its perceived undervaluation.
Exposed assets
BMY
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →